Company: DARE
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0001401914-25-000014
Chunk: 46

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 46
---
— |     |       |     | $91,945 |
| Robin J. Steele, J.D., L.L.M. |     |               |     | $51,500 |     |           |     | $12,945 |     |              |     | $— |     |       |     | $64,445 |

(1) The amounts in this column represent the grant date fair value, determined in accordance with ASC Topic 718, Compensation-Stock Compensation (ASC Topic 718), of stock options granted to the applicable individual. See Note 10. Stock-Based Compensation to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 31, 2025 for details as to the assumptions used to determine the fair value of the awards.

(2) Drs. Blanchard and Ononye-Onyia resigned from our board in June 2024.

As of December 31, 2024, our non-employee directors had stock options outstanding to purchase the following number of shares of our common stock:

| Name                        |     | # of Shares Subject to 
 Outstanding Options    |        |
| Cheryl R. Blanchard, Ph.D.  |     |                        | 14,624 |
| Jessica D. Grossman, M.D.   |     |                        | 19,832 |
| Susan L. Kelley, M.D.       |     |                        | 20,438 |
| Gregory W. Matz, CPA        |     |                        | 19,832 |
| Sophia Ononye-Onyia, Ph.D.  |     |                        | 10,249 |
| William H. Rastetter, Ph.D. |     |                        | 20,437 |
| Robin Steele, J.D., L.L.M.  |     |                        | 20,015 |

#### 2025 Director Compensation Decisions
For 2025, no changes were made with respect to the compensation of our non-employee directors except that the annual retainer payable to non-employee directors was increased from $39,000 to $40,000 and the number of shares subject to the annual award to non-employee directors was increased from 3,333 to 4,500, along with a proportional increase in the size of the initial stock option grant to new directors to maintain the 1.5 multiple for initial stock option grants. Such changes were approved by